The changing face of hepatic encephalopathy: A projection for the next 5 years
Debbie L. Shawcross – 30 December 2016
Novel approaches to the treatment of biliary atresia
Yang Li, Jorge A. Bezerra – 30 December 2016
Mechanisms of portal hypertension: Bench to bedside
Jordi Gracia‐Sancho, Wim Laleman – 30 December 2016
The changing face of hepatic encephalopathy: A projection for the next 5 years
Debbie L. Shawcross – 30 December 2016
Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management
- Read more about Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management
Dennis L. Shung, Guadalupe Garcia‐Tsao – 29 December 2016
Instructions to authors and Information for readers
27 December 2016
Reply
Tammy T. Chang – 27 December 2016
TM6SF2 rs58542926 impacts lipid processing in liver and small intestine
Elizabeth A. O'Hare, Rongze Yang, Laura M. Yerges‐Armstrong, Urmila Sreenivasan, Rebecca McFarland, Carmen C. Leitch, Meredith H. Wilson, Shilpa Narina, Alexis Gorden, Kathy A. Ryan, Alan R. Shuldiner, Steve A. Farber, G. Craig Wood, Christopher D. Still, Glenn S. Gerhard, Janet D. Robishaw, Carole Sztalryd, Norann A.
Inhibition of the sterol regulatory element‐binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in mice
Na Li, Zhang‐Sen Zhou, Yang Shen, Jie Xu, Hong‐Hua Miao, Ying Xiong, Feng Xu, Bo‐Liang Li, Jie Luo, Bao‐Liang Song – 27 December 2016 – Obesity is a critical risk factor for hepatocellular carcinoma (HCC). However, it remains unknown whether inhibition of de novo lipid biosynthesis can suppress HCC.
Dual role of the bile acid receptor Takeda G‐protein‐coupled receptor 5 for hepatic lipid metabolism in feast and famine
Dieter Häussinger, Verena Keitel – 27 December 2016